Flamma Group Passes First FDA Inspection at Malvern, PA CDMO Site
Flamma Group, a contract development and manufacturing organization (CDMO) focused on new chemical entities and late-stage intermediates, announced that its Flamma USA site in Malvern,
AbbVie Invests $380 Million in Two New API Manufacturing Facilities in Illinois
AbbVie has announced a $380 million investment to construct two new active pharmaceutical ingredient (API) manufacturing facilities at its North Chicago, Illinois campus. The facilities
Akums Drugs & Pharmaceuticals Secures EU GMP Certification for Two Indian Facilities
Akums Drugs & Pharmaceuticals Ltd., an India-based contract development and manufacturing organization (CDMO), has secured EU GMP certification for two of its manufacturing facilities located
Bora Pharmaceuticals Extends Collaboration with GSK Through 2030
Bora Pharmaceuticals Co., Ltd. has signed a strategic agreement with GSK to renew a five-year manufacturing partnership. Bora purchased GSK’s Mississauga facility in 2020. The
Bringing Complex Injectable Solutions to Life: A 40-Year Track Record [CDMO Spotlight]
The pharmaceutical industry is witnessing unprecedented demand for sterile injectable products, particularly those with complex formulations and specialized delivery requirements. As molecules become more sophisticated
Seda Establishes Swedish Presence at Medicon Village in Lund
Seda has announced the establishment of a new Swedish presence at Medicon Village in Lund, one of Scandinavia’s life science hubs. The move marks an
U.S. Vaccine Policy Shifts Create a “Chilling” Effect on Global Manufacturing and Innovation
“If you take away funding from research and development, especially for diseases with pandemic potential, those programs will be delayed. We lose time, and some
Morepen Laboratories Secures ₹825 Crore (USD 91 Million) Multi-Year CDMO Mandate
Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organisation (CDMO) mandate valued at approximately ₹825 crore (USD 91 million) from a global pharma
Minaris Joins CIRM Industry Resource Partner Program to Support Cell and Gene Therapy Development
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organisation (CDMO) and multimodality biosafety testing provider, has joined the California Institute for
Trump’s Tariffs Are Off — Or Are They? What Pharma Does Next
On February 20, the U.S. Supreme Court delivered one of the most consequential trade rulings in decades. In a 6–3 decision, the justices held that